Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.4%

4 terminated/withdrawn out of 26 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

44%

7 of 16 completed trials have results

Key Signals

4 recruiting7 with results

Enrollment Performance

Analytics

Phase 1
20(76.9%)
Phase 2
5(19.2%)
Early Phase 1
1(3.8%)
26Total
Phase 1(20)
Phase 2(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT02950766Phase 1Active Not Recruiting

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Role: collaborator

NCT06782932Phase 1Recruiting

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Role: collaborator

NCT05950139Phase 1Recruiting

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Role: collaborator

NCT04201873Phase 1Active Not Recruiting

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Role: collaborator

NCT04525859Phase 1Completed

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Role: lead

NCT03219450Phase 1Recruiting

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Role: collaborator

NCT06064279Phase 1Withdrawn

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Role: collaborator

NCT02834052Phase 1Completed

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Role: collaborator

NCT03835533Phase 1Completed

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Role: collaborator

NCT06343077Phase 2Recruiting

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Role: collaborator

NCT04672291Phase 1Completed

Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults

Role: lead

NCT02334735Phase 2Completed

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Role: collaborator

NCT03262103Phase 1Completed

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Role: collaborator

NCT03721679Phase 1Terminated

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Role: lead

NCT02423863Phase 2Completed

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Role: lead

NCT01437605Phase 2Terminated

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Role: collaborator

NCT00795457Early Phase 1Completed

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

Role: collaborator

NCT02071095Phase 1Completed

Enhancement by Poly-ICLC During HIV-1 Infection

Role: collaborator

NCT01079741Phase 1Completed

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Role: collaborator

NCT00766753Phase 1Completed

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

Role: collaborator